What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)?

Radiotherapy and Oncology

Volumn 48, Issue 3, 1998, Pages 233-248

  Stewart, Fiona ^a   Baas, Paul ^a   Star, Willem ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer patients; Photodynamic therapy; Radiation oncologists

Indexed keywords

AMINOLEVULINIC ACID; BENZOPORPHYRIN DERIVATIVE; ETIOPURPURIN; LUTETIUM TEXAPHYRIN; PHOTOFRIN; PHOTOSENSITIZING AGENT; TALAPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CELL DESTRUCTION; CARCINOMA IN SITU; CLINICAL TRIAL; DNA DAMAGE; HEAD AND NECK CANCER; HUMAN; ILLUMINATION; MOUTH CANCER; NONHUMAN; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; REVIEW;

EID: 0031731920     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(98)00063-2     Document Type: Article

References (160)

1. Adams, G.E., Dische, S., Fowler, J.F. and Thomlinson, R.H. Hypoxic cell sensitisers in radiotherapy. Lancet 1: 186-188, 1976.
2. Allen, R.P., Kessel, D., Tharratt, R.S. and Volz, W. Photodynamic therapy of superficial malignancies with NPe6 in man. In: Photodynamic Therapy and Biomedical Lasers, pp. 441-445. Editors: P. Spinelli, M. Dal Fante and R. Marchesini. International Congress Series 1011, Excerpta Medica, Amsterdam, 1992.
3. Alper, T. Dose fractionation and dose rate. In: Cellular Radiobiology, pp. 164-187. Editor: T. Alper. Cambridge University press, Cambridge, 1979.
4. Anholt, H. and Moan, J. Fractionated treatment of CaD2 tumors in mice sensitized with aluminium phthalocyanine tetrasulphonate. Cancer Lett. 61: 263-267, 1991.
5. Baas, P., Murrer, L., Zoetmulder, F.A., et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br. J. Cancer 76: 819-826, 1997.
6. Baas, P., Van Geel, I.P.J., Oppelaar, H., et al. Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Br. J. Cancer 73: 945-951, 1996.
7. Barr, H., Dix, T., Roberts, D. and Shephard, N. Eradication of high grade dysplasia in columnar lined (Barrett's) oesophagus by photodynamic therapy with oral 5-aminolevulinic acid and 630 nm light. Gut 35: 7, 1994.
8. Barr, H., Shepherd, N.A., Dix, A., Roberts, D.J.H., Tan, W.C. and Krasner, N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348: 584-585, 1996.
9. Barr, H., Tralau, C.J., Boulos, P.B., MacRobert, A.J., Tilly, R. and Bown, S.G. The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury. Photochem. Photobiol. 46: 795-800, 1987.
10. Begg, A.C., Hodgkiss, R.J., McNally, N.J., Middleton, R.W., Stratford, M.R. and Terry, N.H. Fluorescent markers of hypoxic cells: a comparison of two compounds on three cell lines. Br. J. Radiol. 58: 645-654, 1985.
11. Bellnier, D.A., Ho, Y.K., Pandey, R.K., Missert, J.R. and Dougherty, T.J. Distribution and elimination of photofrin II in mice. Photochem. Photobiol. 50: 221-228, 1989.
12. Bellnier, D.A. and Lin, C.W. Photosensitization and split-dose recovery in cultured human urinary bladder carcinoma cells containing nonexchangeable hematoporphyrin derivative. Cancer Res. 45: 2507-2511, 1985.
13. Ben-Hur, E., Kol, R., Riklis, E., Marko, R. and Rosenthal, I. Effect of light fluence rate on mammalian cells photosensitization by chloroaluminium phthalocyanine tetrasulphonate. Int. J. Radiat. Biol. 51: 467-476, 1987.
14. Benson, R.C. Integral photoradiation therapy of multifocal bladder tumors. Eur. Urol. 12: 47-53, 1986.
15. Berenbaum, M.C., Akande, S.L., Bonnett, R., et al. Meso-tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitizer with favourable selectivity. Br. J. Cancer 54: 717-725, 1986.
16. Biel, M.A. Photodynamic therapy and the treatment of neoplastic diseases of the larynx. Laryngoscope 104: 399-403, 1994.
17. Biel, M.A. Photodynamic therapy as an adjuvant intraoperative treatment of recurrent head and neck carcinomas. Arch. Otolaryngol. Head Neck Surg. 122: 1261-1265, 1996.
18. Blant, S.A., Woodtli, A., Fontolliet, C., Van den Bergh, H. and Monnier, P. In vivo fluence rate effect in photodynamic therapy of early cancers with tetra(m-hydroxyphenyl)chlorin. Photochem. Photobiol. 64: 963-968, 1996.
19. Boggan, J.E., Walter, R., Edwards, M.S., et al. Distribution of hematoporphyrin derivative in the rat 9l gliosarcoma brain tumor analyzed by digital video fluorescence microscopy. J. Neurosurg. 61: 1113-1119, 1984.
20. Boyle, R.W. and Dolphin, D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol. 64: 469-485, 1996.
21. Braichotte, D., Savary, J., Glanzmann, T., Monnier, P., Wagnieres, G. and Van den Bergh, H. Optimizing light dosimetry in photodynamic therapy of the bronchi by fluorescence spectroscopy. Lasers Med. Sci. 11: 247-254, 1996.
22. Braichotte, D., Savary, J., Glanzmann, T., et al. Clinical pharmacokinetic studies of tetra(meta-hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths. Int. J. Cancer 63: 198-204, 1995.
23. Braichotte, D., Savary, J., Monnier, P., Wagnieres, G. and Van den Bergh, H. Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy. Lasers Surg. Med. 19: 340-346, 1996.
24. Braichotte, D., Wagnieres, G., Philippoz, J.M., Ris, H.B. and Van den Bergh, H. Preliminary clinical results on a second generation photosensitizer: mTHPC. In: Photodynamic Therapy and Biomedical Lasers, pp. 461-465. Editors: P. Spinelli, M. Dal Fante and R. Marchesini. Elsevier, Amsterdam, 1992.
25. Bugelski, P.J., Porter, C.W. and Dougherty, T.J. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res. 41: 4606-4612, 1981.
26. Cairnduff, F., Stringer, M.R., Hudson, E.J., Ash, D.V. and Brown, S.B. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br. J. Cancer 69: 605-608, 1994.
27. Calzavara-Pinton, P.G., Szeimies, R.-M., Ortel, B. and Zane, C. Photodynamic therapy with systemic administration of photosensitizers in dermatology. J. Photochem. Photobiol., Ser. B Biol. 36: 225-231, 1996.
28. Chapman, J.D., Stobbe, C.C., Arnfield, M.R., Santus, R., Lee, J. and McPhee, M.S. Oxygen dependency of tumor cell killing in vitro by light-activated Photofrin II. Radiat. Res. 126: 73-79, 1991.
29. D'Hallewin, M.A., Baert, L., Marijnissen, J.P.A. and Star, W.M. Whole bladder wall photodynamic therapy with in situ light dosimetry for carcinoma in situ of the bladder. J. Urol. 148: 1152-1155, 1992.
30. Davila, J. and Harriman, A. Photosensitized oxidation of biomaterials and related model compounds. Photochem. Photobiol. 50: 29-35, 1989.
31. Dilkes, M.G., DeJode, M.L., Rowntree-Taylor, A., McGilligan, J.A., Kenyon, G.S. and McKelvie, P. m-THPC photodynamic therapy for head and neck cancer. Lasers Med. Sci. 11: 23-29, 1996.
32. Dougherty, T.J. Photodynamic therapy of malignant tumors. CRC Crit. Rev. Oncol./Hematol. 2: 83-116, 1984.
33. Dougherty, T.J., Cooper, M.T. and Mang, T.S. Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg. Med. 10: 485-488, 1990.
34. Elkind, M.M., Sutton-Gilbert, H., Moses, W.B., Alescio, T. and Swain, R.W. Radiation response of mammalian cells grown in culture. Radiat. Res. 25: 359-376, 1965.
35. Evensen, J.F. and Moan, J. Photodynamic therapy of C3H tumours in mice: effect of drug/light dose fractionation and misonidazole. Lasers Med. Sci. 3: 1-6, 1988.
36. Fan, K., Hopper, C., Speight, P., Buonaccorsie, G. and Bown, S. Photodynamic therapy using mTHPC for malignant disease in the oral cavity. Int. J. Cancer 73: 25-32, 1997.
37. Fan, K.M., Hopper, C., Speight, P.M., Buonaccorsie, G., MacRobert, A.J. and Bown, S.G. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 78: 1374-1383, 1996.
38. Fingar, V.H., Wieman, T.J. and Weber Doak, K. Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res. 50: 2599-2603, 1990.
39. Fingar, V.H., Wieman, T.J., Wiehle, S.A. and Cerrito, P.B. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res. 52: 4914-4921, 1992.
40. Fisher, A.M.R., Murphree, A.L. and Gomer, C.J. Clinical and preclinical photodynamic therapy. Lasers Surg. Med. 17: 2-31, 1995.
41. Foote, C.S. Definition of type I and type II photosensitized oxidation. Photochem. Photobiol. 54: 659, 1991.
42. Foster, T.H. and Gao, L. Dosimetry in photodynamic therapy: oxygen and the critical importance of capillary density. Radiat. Res. 130: 379-383, 1992.
43. Foster, T.H., Hartely, D.F., Nichols, M.G. and Hilf, R. Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res. 53: 1249-1254, 1993.
44. Foster, T.H., Murant, R.S., Bryant, R.G., Knox, R.S., Gibson, S.L. and Hilf, R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat. Res. 126: 296-303, 1991.
45. Foster, T.H., Primavera, M.C., Marder, v.J., Hilf, R. and Sporn, L. Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res. 51: 3261-3266, 1991.
46. Gibson, S.L., VanDerMeid, K.R., Murant, R.S., Raubertas, R.F. and Hilf, R. Effects of various photoradiation regimens on the antitumor efficiency of photodynamic therapy for R3230 AC mammary carcinomas. Cancer Res. 50: 7236-7241, 1990.
47. Gluckman, J.L. Photodynamic therapy for head and neck neoplasms. Otolaryngol. Clin. North Am. 24: 1559-1567, 1991.
48. Gomer, C.J. and Ferrario, A. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model. Cancer Res. 50: 3985-3990, 1990.
49. Gomer, C.J., Rucker, N., Ferrario, A. and Murphree, A.L. Expression of potentially lethal damage in Chinese hamster cells exposed to hematoporphyrin derivative photodynamic therapy. Cancer Res. 46: 3348-3352, 1986.
50. Grant, W.E., Hopper, C., Speight, P.M., MacRobert, A.J. and Bown, S.G. Photodynamic therapy of malignant and premalignant lesions in patients with 'field cancerization' of the oral cavity. J. Laryngol. Otol. 107: 1140-1145, 1993.
51. Graschew, G., Shopova, M., Anastassova, G. and Chakarova, A. Light dose fractionation versus single-dose irradiation in photodynamic therapy of tumours. Lasers Med. Sci. 3: 173-177, 1988.
52. Grosjean, P., Savary, J.F., Mizeret, J., et al. Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyl)chlorin. J. Clin. Laser Med. Surg. 14: 281-287, 1996.
53. Harty, J.I., Amin, M., Wieman, T.J., Tseng, M.T., Ackerman, D. and Broghamer, W. Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J. Urol. 141: 1341-1346, 1989.
54. Henderson, B.W. and Dougherty, T.J. How does photodynamic therapy work. Photochem. Photobiol. 55: 145-157, 1992.
55. Henderson, B.W. and Fingar, V.H. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res. 47: 3110-3114, 1987.
56. Henderson, B.W. and Fingar, V.H. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem. Photobiol. 49: 299-304, 1989.
57. Henderson, B.W. and Miller, A.C. Effects of scavengers of reactive oxygen and radical species on cell survival following photodynamic treatment in vitro: comparison to ionizing radiation. Radiat Res. 108: 196-205, 1986.
58. Henderson, B.W., Waldow, S.M., Mang, T.S., Potter, W.R., Malone, P.B. and Dougherty, T.J. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 45: 572-576, 1985.
59. Henning, J.P., Fournier, R.L. and Hampton, J.A. A transient mathematical model of oxygen depletion during photodynamic therapy. Radiat. Res. 142: 221-226, 1995.
60. Husain, D., Miller, J.W., Michaud, N., Connolly, E., Flotte, T.J. and Gragoudas, E.S. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch. Ophthalmol. 114: 978-985, 1996.
61. Jovanoic, A., Van der Tol, I.G.H., Kostense, P.J., Schulten, E.A.J.M., Snow, G.B. and Van der Waal, I. Second respiratory and upper digestive tract cancer following oral squamous cell carcinoma. Oral Oncol. Eur. J. Cancer 30b: 225-230, 1994.
62. Kaplan, M.J., Somers, R.G., Greenberg, R.H. and Ackler, J. Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin etiopurpurin. J. Surg. Oncol. 67: 121-125, 1998.
63. Katoh, T., Asahara, T., Naitoh, Y., et al. In vivo intravascular laser photodynamic therapy in rabbit atherosclerotic lesions using a lateral direction fiber. Lasers Surg. Med. 20: 373-381, 1997.
64. Kaye, A.H. and Hill, J.S. Photodynamic therapy of brain tumours. Ann. Acad. Med. Singapore 22: 470-481, 1993.
65. Kennedy, J.C. and Pottier, R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol., Ser. B 14: 275-292, 1992.
66. Kennedy, J.C., Pottier, R.H. and Pross, D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol., Ser. B 6: 143-148, 1990.
67. Kessel, D., Thompson, P., Musselman, B. and Chang, C.K. Probing the structure and stability of the tumor-localizing derivative of hematoporphyrin by reductive cleavage with LiAlH4. Cancer Res. 47: 4642-4645, 1987.
68. Kostron, H., Obwegeser, A. and Jakober, R. Photodynamic therapy in neurosurgery: a review. J. Photochem. Photobiol., Ser. B 36: 157-168, 1996.
69. Kreimer-Birnbaum, M. Modified porphyrins, chlorins, phthalocyanines, and purpurins: second-generation photosensitizers for photodynamic therapy. Semin. Hematol. 26: 157-173, 1989.
70. Kriegmair, M., Baumgartner, R., Lumper, W., Waidelich, R. and Hofstetter, A. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br. J. Urol. 77: 667-671, 1996.
71. Levy, J.G. Photosensitizers in photodynamic therapy. Semin. Oncol. 21: 4-10, 1994.
72. Lightdale, C.J., Heier, S.K., Marcon, N.E., et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest. Endosc. 42: 507-512, 1995.
73. Lilge, L., Dabrowski, W., Holdsworth, D.W., et al. Light delivery and dosimetry for photodynamic therapy in an ovarian cancer mouse model. Proc. SPIE 2133: 150-161, 1994.
74. Lowdell, C.P., Ash, D.V., Driver, I. and Brown, S.B. Interstitial photodynamic therapy. Clinical experience with diffusing fibres in the treatment of cutaneous and subcutaneous tumours. Br. J. Cancer 67: 1398-1403, 1993.
75. Lui, H. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. Semin. Oncol. 21: 11-14, 1994.
76. Ma, L.W., Moan, J. and Berg, K. Comparison of the photobleaching effect of three photosensitizing agents: meso-tetra(m-hydroxyphenyl)chlorin, meso-tetra(m-hydroxyphenyl)porphyrin and Photofrin during photodynamic therapy. Lasers Med. Sci. 9: 127-132, 1994.
77. Mang, T.S. and Wieman, T.J. Photodynamic therapy in the treatment of pancreatic carcinoma: dihematoporphyrin ether uptake and photobleaching kinetics. Photochem. Photobiol. 46: 853-858, 1987.
78. Marijnissen, J.P.A., Jansen, H. and Star, W.M. Treatment system for whole bladder wall photodynamic therapy with in vivo monitoring and control of light dose rate and dose. J. Urol. 142: 1351-1355, 1989.
79. Marijnissen, J.P.A., Star, W.M., In't Zandt, H.J.A., D'Hallewin, M.A. and Baert, L. In situ light dosimetry during whole bladder wall photodynamic therapy: clinical results and experimental verification. Phys. Med. Biol. 38: 567-582, 1993.
80. Marijnissen, J.P.A., Versteeg, A.A.C., Star, W.M. and Van Putten, W.L.J. Tumor and normal tissue response to interstitial photodynamic therapy of the rat R-I rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 22: 963-972, 1992.
81. Matthews, W., Cook, J., Mitchell, J.B., Perry, R.R., Evans, S. and Pass, H.I. In vitro photodynamic therapy of human lung cancer: investigation of dose-rate effects. Cancer Res. 49: 1718-1721, 1989.
82. McCaughan, J.S. Photodynamic therapy of endobronchial and esophageal tumors: an overview. J. Clin. Laser Med. Surg. 14: 223-233, 1996.
83. Messmann, H., Mlkvy, P., Buonaccorsie, G., Davies, C.L., MacRobert, A.J. and Bown, S.G. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br. J. Cancer 72: 589-594, 1995.
84. Miles, D.R. and Young, S.W. Repeated treatment of RIF-1 tumours with photodynamic therapy (PDT) using lutetium texaphyrin (PCI-0123). Photochem. Photobiol. 65: 47s, 1997.
85. Mitchell, J.B., McPherson, S., DeGraff, W., Gamson, J., Zabell, A. and Russo, A. Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of Chinese hamster cells. Cancer Res. 45: 2008-2011, 1985.
86. Moan, J. Effect of bleaching of porphyrin sensitizers during photodynamic therapy. Cancer Lett. 33: 45-53, 1986.
87. Moan, J., Rimington, C. and Malik, Z. Photoinduced degradation and modification of Photofrin II in cells in vitro. Photochem. Photobiol. 47: 363-367, 1988.
88. Moghissi, K., Dixon, K., Hudson, E. and Stringer, M. Photodynamic therapy of oesophageal cancer. Lasers Med. Sci. 10: 67-71, 1995.
89. Morgan, A.R., Garbo, G.M., Krivak, T., et al. New sensitizers for PDT. Proc. SPIE Optical Methods Tumor Treatment Early Diagnosis 1426: 350-355, 1991.
90. Morlet, L., Vonarx-Coinsmann, V., Lenz, P., et al. Correlation between meta(tetrahydroxyphenyl)chlorin (m-THPC) biodistribution and photodynamic effects in mice. Photochem. Photobiol. 28: 25-32, 1995.
91. Morton, C.A., Whitehurst, C., Moseley, H., McColl, J.H., Moore, J.V. and Mackie, R.M. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br. J. Dermatol. 135: 766-771, 1996.
92. Muller, P.J. and Wilson, B.C. Photodynamic therapy of malignant primary brain tumours: clinical effects, post-operative ICP, and light penetration of the brain. Photochem. Photobiol. 46: 929-935, 1987.
93. Murrer, L.H.P., Marijnissen, J.P.A., Baas, P., Van Zandwijk, N. and Star, W.M. Applicator for light delivery and in situ light dosimetry during endobronchial photodynamic therapy: first measurements in humans. Lasers Med. Sci. 12: 253-259, 1997.
94. Naito, K., Hisazumi, H., Uchibayashi, T., et al. Integral laser photodynamic treatment of refractory multifocal bladder tumors. J. Urol. 146: 1541-1545, 1991.
95. Nseyo, U.O., Dougherty, T.J. and Sullivan, L. Photodynamic therapy in the management of resistant lower urinary tract carcinoma. Cancer 60: 3113-3119, 1987.
96. Obwegeser, A., Ortler, M., Seiwald, M., Ulmer, H. and Kostron, H. Therapy of glioblastoma multiforme: a cumulative experience of 10 years. Acta Neurochir. (Wien) 137: 29-33, 1995.
97. Okunaka, T., Kato, H., Conaka, C., Yamamoto, H., Bonaminio, A. and Eckhauser, M.L. Photodynamic therapy of esophageal carcinoma. Surg. Endosc. 4: 150-153, 1990.
98. Oleinick, N.L., Agarwal, M.M.L., Berger, N.A., et al. Signal transduction and metabolic changes during tumor cell apoptosis following phthalocyanine sensitized photodynamic therapy. Proc. SPIE Optical Methods Tumor Treatment Detection 1881: 252-261, 1993.
99. Overholt, B., Panjehpour, M., Tefftellar, E. and Rose, M. Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus. Gastrointest. Endosc. 39: 73-76, 1993.
100. Pass, H.I., DeLaney, T.F., Tochner, Z., et al. Intrapleural photodynamic therapy: results of a phase I trial. Ann. Surg. Oncol. 1: 28-37, 1994.
101. Peng, Q., Berg, K., Moan, J., Kongshaug, M. and Nesland, J.M. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem. Photobiol. 65: 235-251, 1997.
102. Peng, Q., Moan, J., Ma, L.W. and Nesland, J.M. Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res. 55: 2620-2626, 1995.
103. Pogue, B.W. and Hasan, T. A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiat Res. 147: 551-559, 1997.
104. Reed, M.W., Schuske, D.A., Ackermann, D.M., Harty, J.I., Wieman, T.J. and Miller, F.N. The response of the rat urinary bladder microcirculation to photodynamic therapy. J. Urol. 142: 865-868, 1989.
105. Reed, M.W., Schuske, D.A. and Miller, F.N. Prostanoid antagonists inhibit the response of the microcirculation to 'early' photodynamic therapy. Radiat. Res. 127: 292-296, 1991.
106. Reed, M.W.R., Mullins, A.P., Anderson, G.L., Miller, F.N. and Wieman, T.J. The effect of photodynamic therapy on tumor oxygenation. Surgery 106: 94-99, 1989.
107. Regula, J., MacRobert, A.J., Gorchein, A., et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX - a pilot study. Gut 36: 67-75, 1995.
108. Renschler, M.F., Yuen, A., Panella, T.J., et al. Photodynamic therapy trials with lutetium texaphyrin PCI-0123 (LU-TEX). Photochem. Photobiol. 65: 47s, 1997.
109. Richter, A.M., Cerruti-Sola, S., Sternberg, E.D., Dolphin, D. and Levy, J.G. Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J. Photochem. Photobiol., Ser. B 5: 231-244, 1990.
110. Richter, A.M., Kelly, B., Chow, J., et al. Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J. Natl. Cancer Inst. 79: 1327-1332, 1987.
111. Richter, A.M., Waterfield, E., Jain, A.K., et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumor model. Br. J. Cancer 63: 87-93, 1991.
112. Richter, A.M., Yip, S., Waterfield, E., Logan, P.M., Slonecker, C.E. and Levy, J.G. Mouse skin photosensitization with benzoporphyrin derivatives and Photofrin macroscopic and microscopic evaluation. Photochem. Photobiol. 53: 281-286, 1991.
113. 2 for basal cell naevus syndrome: a case report. Clin. Ther. 19: 639-641, 1997.
114. Ris, H., Altermatt, H.J., Nachbur, B., et al. Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers Surg. Med. 18: 39-45, 1996.
115. Ris, H.B., Altermatt, H.J., Inderbitzi, R., et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br. J. Cancer 64: 1116-1120, 1991.
116. Ris, H.B., Altermatt, H.J., Nachbur, B., et al. Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma. Int. J. Cancer 53: 141-146, 1993.
117. Robinson, D.J., De Bruijn, H.S., van der Veen, N., Stringer, M.R., Brown, S.B. and Star, W.M. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem. Photobiol. 67: 140-149, 1998.
118. Ronn, A.M., Nouri, M., Lofgren, L.A., et al. Human tissue levels and plasma pharmacokinetics of temoporphin (FOSCAN, m-THPC). Lasers Med. Sci. 11: 267-272, 1996.
119. Santus, R., Stobbe, C.C., McPhee, M.S. and Chapman, J.D. Protection against light-activated photofrin II killing of tumor cells by nitroimidazoles. Radiat. Res. 130: 31-37, 1992.
120. Savary, J., Monnier, P., Wagnieres, G., Braichotte, G., Fontolliet, C. and Van den Bergh, H. Preliminary clinical studies of photodynamic therapy with meso-tetrahydroxyphenyl chlorin (m-THPC) as a photosensitizing agent for the treatment of early pharyngeal, oesophageal and bronchial carcinomas. Proc. SPIE 2078: 330-340, 1994.
121. Savary, J.F., Monnier, P., Fontolliet, C., et al. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Arch. Otolaryngol. Head Neck Surg. 123: 162-168, 1997.
122. Schweitzer, V.G., Bologna, S. and Batra, S.K. Photodynamic therapy for treatment of esophageal cancer: a preliminary report. Laryngoscope 103: 699-703, 1993.
123. Selman, S.H. and Keck, R.W. The effect of transurethral light on the canine prostate after sensitization with the photosensitizer tin (II) etiopurpurin dichloride: a pilot study. J. Urol. 152: 2129-2132, 1994.
124. Selman, S.H., Kreimer-Birnbaum, M., Klaunig, J.E., Goldblatt, P.J., Keck, R.W. and Britton, S.L. Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. Cancer Res. 44: 1924-1927, 1984.
125. Sibille, A., Lambert, R., Souquet, J.-C., Sabben, G. and Descos, F. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 108: 337-344, 1995.
126. Sitnik, T.M., Hampton, J.A. and Henderson, B.W. Reduction of tumor oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br. J. Cancer 1998, in press.
127. Star, W.M. Light dosimetry in vivo. Phys. Med. Biol. 42: 763-787, 1997.
128. Star, W.M., Marijnissen, H.P.A., Jansen, H., Keijzer, M. and Van Gemert, M.J.C. Light dosimetry for photodynamic therapy by whole bladder wall irradiation. Photochem. Photobiol. 46: 619-624, 1987.
129. Star, W.M., Marijnissen, H.P.A., Van den Berg-Blok, A.E., Versteeg, J.A., Franken, K.A.P. and Reinhold, H.S. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 46: 2532-2540, 1986.
130. Star, W.M., Wilson, B.C. and Patterson, M.S. Light delivery in photodynamic therapy of solid tumors. In: Photodynamic Therapy. Basic Principles and Clinical Applications, pp. 335-368. Editors: B.W. Henderson and T.J. Dougherty. Marcel Dekker, New York, 1992.
131. Stenzl, A., Eder, I., Kostron, H., Klocker, H. and Bartsch, G. Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolaevulinic acid (delta-ALA) for superficial bladder cancer. J. Photochem. Photobiol., Ser. B 36: 233-236, 1996.
132. Svanberg, K., Andersson, T., Killander, D., et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br. J. Dermatol. 130: 743-751, 1994.
133. Takita, H. and Dougherty, T.J. Intracavitary photodynamic therapy for malignant pleural mesothelioma. Semin. Surg. Oncol. 11: 368-371, 1995.
134. Tan, I.B., Oppelaar, H., Ruevekamp-Helmers, M.C., Timmers, A. and Stewart, F.A. The importance of in situ light dosimetry for photodynamic therapy of oral cavity tumors. Submission 1998.
135. Trauner, K.B. and Hasan, T. Photodynamic treatment of rheumatoid and inflammatory arthritis. Photochem. Photobiol. 64: 740-750, 1996.
136. Tromberg, B.J., Orenstein, A., Kimel, S., et al. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem. Photobiol. 52: 375-385, 1990.
137. Uchibayashi, T., Koshida, K., Kunimi, K. and Hisazumi, H. Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder. Br. J. Cancer 71: 625-628, 1995.
138. Van Benthem, H.E., Sterenborg, H.J.C.M., Van der Meulen, F.W. and Van Gemert, M.J.C. Performance of a light applicator for photodynamic therapy in the oral cavity: calculations and measurements. Phys. Med. Biol. 42: 1689-1700, 1997.
139. van der Veen, N., van Leengoed, H.L. and Star, W.M. In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations. Br. J. Cancer 70: 867-872, 1994.
140. Van Geel, I.P., Oppelaar, H., Marijnissen, J.P.A. and Stewart, F.A. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. Radiat. Res. 145: 602-609, 1996.
141. Van Geel, I.P.J., Oppelaar, H., Oussoren, Y. and Stewart, F.A. Changes in perfusion of mouse tumours after photodynamic therapy. Int. J. Cancer 56: 224-228, 1994.
142. Van Gemert, J.C., Berenbaum, M.C. and Gijsbers, G.H.M. Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. Br. J. Cancer 52: 43-49, 1985.
143. Van Staveren, H.J., Beek, J.F., Ramaekers, J.W.H., Keijzer, M. and Star, W.M. Integrating sphere effect in whole bladder wall photodynamic therapy: I. 532 nm versus 630 nm optical irradiation. Phys. Med. Biol. 39: 947-959, 1994.
144. Van Zandwijk, N., Sutedja, G., Baas, P. and Stewart, F.A. An emerging role for photodynamic therapy in lung cancer. Form Trends Exp. Clin. Med. 3: 33-39, 1993.
145. Veenhuizen, R.B., Oppelaar, H., Ruevekamp, M., Schellens, J., Dalesio, O. and Stewart, F.A. Does tumour uptake of Foscan determine PDT efficacy? Int. J. Cancer 73: 236-239, 1997.
146. Veenhuizen, R.B., Ruevekamp, M., Oppelaar, H., Helmerhorst, T., Kenemans, P. and Stewart, F. Foscan mediated photodynamic therapy for a peritoneal cancer model: drug distribution and efficacy studies. Int. J. Cancer 73: 230-235, 1997.
147. Veenhuizen, R.B. and Stewart, F.A. The importance of fluence rate in photodynamic therapy: is there a parallel with ionizing radiation dose-rate effects? Radiother. Oncol. 37: 131-135, 1995.
148. Verheij, M., Dewit, L.G., Boomgaard, M.N., Brinkman, H.J. and van Mourik, J.A. Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Willebrand factor. Radiat. Res. 137: 202-207, 1994.
149. Verheij, M., Koomen, G.C., van Mourik, J.A. and Dewit, L. Radiation reduces cyclooxygenase activity in cultured human endothelial cells at low doses. Prostaglandins 48: 351-366, 1994.
150. Wagnieres, G., Monnier, P., Savary, M., Cornaz, P., Chatelain, A. and Van den Bergh, H. Photodynamic therapy of early cancer in the upper aerodigestive tract and bronchi: instrumentation and clinical results. In: Future Directions and Applications in Photodynamic Therapy, pp. 249-271. Proc. SPIE: IS6 1990.
151. Walther, M.M., DeLaney, T.F., Smith, P.D., et al. Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder. Urology 50: 199-206, 1997.
152. Wenig, B.L., Kurtzman, D.M., Grossweiner, L.I., et al. Photodynamic therapy in the treatment of squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 116: 1267-1270, 1990.
153. Wharen, R.E., Anderson, R.E. and Laws, E.R. Quantitation of hematoporphyrin derivative in human gliomas, experimental central nervous system tumors, and normal tissues. Neurosurg. 12: 446, 1983.
154. Whelpton, R., Michael-Titus, A.T., Jamdar, R.P., Abdillahi, K. and Grahn, M.F. Distribution and excretion of radiolabeled temoporfin in a murine tumor model. Photochem. Photobiol. 63: 885-891, 1996.
155. Whitehurst, C., Humphries, J.D. and Moore, J.V. Development of an alternative light source to lasers for photodynamic therapy: 2. Comparative in vivo tumour response characteristics. Lasers Med. Sci. 10: 121-126, 1995.
156. Wierrani, F., Fiedler, D., Grin, W., Henry, M., Krammer, B. and Grunberger, W. Intraoperative meso-tetrahydroxyphenylchlorin-based photodynamic therapy in metastatic gynecologic cancer tissue: initial results. J. Gynecol. Surg. 13: 23, 1997.
157. Wierrani, F., Fiedler, D., Schnitzhofer, G., et al. A new approach to cancer therapy due to appropriate uptake and retention kinetics of meta-tetrahydroxy-phenylchlorin in a human fibroblast cell line. Cancer Biochem. Biophys. 15: 171-176, 1996.
158. Wilson, B.C., Muller, P.J. and Yanch, J.C. Instrumentation and light dosimetry for intra-operative photodynamic therapy (PDT) of malignant brain tumours. Phys. Med. Biol. 31: 125-133, 1986.
159. Wilson, B.C., Patterson, M.S. and Lilge, L. Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med. Sci. 12: 182-199, 1997.
160. Wilson, B.D., Mang, T.S., Cooper, M. and Stoll, H.L. Use of photodynamic therapy for the treatment of extensive basal cell carcinomas. Facial Plastic Surg. 6: 185-189, 1989.